2 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 5 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
Follow Radiopharmaceuticals: new trials by email Literature Review of Radiopharmaceuticals trials Research Report on Radiopharmaceuticals
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC Radiopharmaceuticals - Prostate Cancer | Phase 1 / Phase 2 | Recruiting | C Ray Therapeutics | 90 | 2026-05-22 | 2026-05-29 |
| Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer 177Lu-PSMA-1 (radiopharmaceutical) - Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Completed | Centre Leon Berard | 6 | 2023-11-09 | 2026-04-24 |
| PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy PET/CT, radioactive drug (tracer) - Cancer | Phase 1 / Phase 2 | Completed | Mayo Clinic | 6 | 2020-08-14 | 2023-09-13 |
| PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During Chemotherapy With Antiangiogenic Agents radiopharmaceutical (Flotegatide (18F) or RGD (68Ga) - Advanced Head and Neck Carcinoma, Advanced Non-small Cell Lung Carcinoma | Phase 2 | Terminated | Assistance Publique - Hôpitaux de Paris | 1 | 2015-03-20 | 2022-07-19 |
| An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours Lu-DOTA-TATE - Neuroendocrine Carcinoma | Phase 2 | Active not recruiting | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 66 | 2014-07-01 | 2026-10-05 |
Carcinoma, Neuroendocrine (1) · Clear-cell metastatic renal cell carcinoma (1) · Neoplasms (1) · Prostatic Neoplasms (1)
Assistance Publique - Hôpitaux de Paris (1) · C Ray Therapeutics (1) · Centre Leon Berard (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Mayo Clinic (1)
France (2) · Canada (1) · China (1) · United States (1)
Dingwei Ye, MD, PhD (1) · John Bois, MD (1) · Nianzeng Xing, MD, PhD (1) · Yan Wu, MD (1)
2014 (1)